<DOC>
	<DOCNO>NCT01315132</DOCNO>
	<brief_summary>This research study use drug call cyclophosphamide decrease incidence GVHD match sibling hematopoietic stem cell transplant . In , goal study increase overall survival .</brief_summary>
	<brief_title>A Study Bone Marrow Transplantation Using Fully-Matched Relatives Donors Patients With Hematological Malignancies</brief_title>
	<detailed_description>This research protocol develop patient undergo matched-sibling hematopoietic stem cell transplant ( HSCT ) . The patient treat accord 2 step allogeneic HSCT protocol receive cyclophosphamide induce in-vivo tolerization autologous allogeneic lymphocyte , follow allogeneic CD34-selected HSCT . The primary research question relate immune reconstitution , incidence GVHD , relapse patient receive lymphocyte treatment type allogeneic HSCT impact overall survival .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Any patient hematologic oncologic diagnosis allogeneic HSCT think beneficial , frontline therapy already apply . Patients consider highrisk following : 1 . Age &gt; 50 year 2 . ECOG Performance status &lt; 2 3 . Acute leukemia : require one chemotherapy regimen obtain 1st CR ; second great CR , 1st relapse ; ph+ ALL 4 . CML 2nd chronic phase , accelerated phase , blastic phase 5 . MDS IPS Intermediate 2 great 6 . Any myeloproliferative disorder 7 . Hodgkin lymphoma : relapse , refractory , primary induction failure 8 . NonHodgkin lymphoma : relapse , refractory , primary treatment failure , eligible autologous HSCT 9 . Other condition list assessed highrisk PI 2 . Patients must relate donor either HLAidentical one antigen mismatch HLA A ; B ; C ; DR locus . 3 . Patients must adequate organ function : 1 . LVEF &gt; 45 % 2 . DLCO ( adjust hemoglobin ) &gt; 45 % predict 3 . Adequate liver function define serum bilirubin &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal 4 . Creatinine clearance &gt; 60 ml/min 4 . Patients must willing use contraception childbearing potential 5 . Able give inform consent 1 . ECOG performance status 3 4 . 2 . HIV positive 3 . Active involvement central nervous system malignancy 4 . Psychiatric disorder would preclude patient sign informed consent 5 . Pregnancy 6 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myeloablative Hematopoietic Stem Cell Transplant</keyword>
	<keyword>Cyclophosphamide tolerization</keyword>
	<keyword>2 Step Approach</keyword>
	<keyword>Hematological malignancy</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
</DOC>